Vasopeptidase inhibition

Current Opinion in Nephrology and Hypertension

Volumn 9, Issue 5, 2000, Pages 465-468

  Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTIHYPERTENSIVE AGENT; ATRIAL NATRIURETIC FACTOR; CALCIUM ANTAGONIST; CHOLESTEROL; CYCLIC GMP; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; LISINOPRIL; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; PEPTIDASE; SODIUM;

ATHEROMA; ATHEROSCLEROSIS; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; ENZYME INHIBITION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY METABOLISM; NONHUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RABBIT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM INTAKE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS; KIDNEY FAILURE, CHRONIC; NEPRILYSIN;

EID: 0033855988     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-200009000-00001     Document Type: Note

References (30)

1. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones
2. Role of endopeptidase-24.11 in the activation of atrial natriuretic peptide
3. Renal metabolism of atrial natriuretic peptide in the rat
4. Characterization and control of expression of neutral endopeptidase (NEP) in cultured vascular smooth muscle cells from the rabbit renal cortex
5. Role of neutral endopeptidase in the metabolism of endothelin
6. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11)
7. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure
8. Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: A potential therapeutic approach in hypertension
9. Vascular actions of brain natriuretic peptide: Modulation by atherosclerosis and neutral endopeptidase inhibition
10. Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis
11. Chronic inhibition of endopeptidase 24.11 in essential hypertension: Evidence for enhanced atrial natriuretic peptide and angiotensin II
12. The effect of the neutral endopeptidase inhibitor drug, canddoxatril, on circulating levels of two of the most potent vasoactive peptides
13. Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure
14. Renal response to atrial natriuretic factor is modulated by intrarenal angiotensin II
15. Dual mechanism of angiotensin II inhibits ANP-induced mesangial cGMP accumulation
16. Angiotensin decreases cyclic GMP accumulation produced by a trial natriuretic factor
17. Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus
18. Vasopeptidase inhibition: A new concept in blood pressure management
19. Dual metalloprotease inhibitors. Mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase
20. Long-term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure
21. The cardiac hormone atrial natriuretic peptide mediates hemodynamic actions of dual enzyme inhibition in early left ventricular dysfunction
22. Effects of omaptrilat in low, normal, and high renin experimental hypertension
23. Monotherapy treatment success rate of omaptrilat, a vasopeptidase inhibitor, compared with lisinopril and amlodipine in mild to moderate hyeprtension
24. Randomized double-blind comparison of omapatrilat with amlodipine in mild-to-moderate hypertension
25. Vasopeptidase inhibitor or angiotensin converting enzyme inhibitor in heart failure? Results of the IMPRESS trial
26. Acute NEP/ACE inhibition by omapatrilat is superior to ACE inhibition alone in mediating favorable cardiorenal and humoral actions in mild heart failure
27. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction
28. Differential cardiovascular actions of omapatrilat versus ace inhibitor and diuretics in early left ventricular dysfunction
29. Efficacy and safety of omapatrilat, a vasopeptidase inhibitor
30. Bradykinin metabolism in the infarcted and hypertrophied rat heart: Respective role of angiotensin converting enzyme and neutral endopeptidase 24.11